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Background: Allergen-specific immunotherapy can induce long-term suppression of
allergic symptoms, reduce medication use, and prevent exacerbations of allergic rhini-
tis and asthma. Current treatment is based on crude allergen extracts, which contain
immunostimulatory components such as b-glucans, chitins, and endotoxin. Use of
purified or recombinant allergens might therefore increase efficacy of treatment.
Aims: Here, we test application of purified natural group 1 and 2 allergens from
Dermatophagoides pteronyssinus (Der p) for subcutaneous immunotherapy (SCIT)
treatment in a house dust mite (HDM)-driven mouse model of allergic asthma.
Materials and methods: HDM-sensitized mice received SCIT with crude HDM
extract, a mixture of purified Der p1 and 2 (DerP1/2), or placebo. Upon challenges,
we measured specific immunoglobulin responses, allergen-induced ear swelling
response (ESR), airway hyperresponsiveness (AHR), and inflammation in bron-
choalveolar lavage fluid (BAL) and lung tissue.
Results: ESR measurement shows suppression of early allergic response in HDM-
SCIT– and DerP1/2-SCIT–treated mice. Both HDM-SCIT and DerP1/2-SCIT are able
to suppress AHR and eosinophilic inflammation. In contrast, only DerP1/2-SCIT is
able to significantly suppress type 2 cytokines in lung tissue and BAL fluid. More-
over, DerP1/2-SCIT treatment is uniquely able suppress CCL20 and showed a trend
toward suppression of IL-33, CCL17 and eotaxin levels in lung tissue.
Discussion: Taken together, these data show that purified DerP1/2-SCIT is able to
not only suppress AHR and inflammation, but also has superior activity toward sup-
pression of Th2 cells and HDM-induced activation of lung structural cells including
airway epithelium.
Conclusions: We postulate that treatment with purified natural major allergens
derived from HDM will likely increase clinical efficacy of SCIT.
K E YWORD S
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1 | INTRODUCTION
Allergen-specific immunotherapy (SIT) has been used for the treatment
of allergic disorders for over a century.1 Specific immunotherapy (SIT)
has been shown to induce durable immunological changes in response
to the allergen, through generating neutralizing antibodies, through sup-
pressing numbers and activity of allergen-specific Th2 cells and type 2
innate lymphoid cells (ILC2s), and by inducing regulatory T-cell activity.2
Successful SIT has been associated with enhanced release of IL-10 in
PBMC cultures restimulated with allergen,3 serum-dependent suppres-
sion of cross-presentation by B cells,4 and selective loss of those T-cell
clones with allergen-epitope specificities that are increased in atopic
individuals compared to healthy controls.5,6 Specific immunotherapy
(SIT) induces long-term tolerance to the allergen, as evidenced by the
absence of allergic manifestations upon repeated allergen challenges.1
Current SIT regimens routinely employ a crude extract of the
allergen for injection, subcutaneous immunotherapy (SCIT) or tablet
and droplet formulation, sublingual immunotherapy (SLIT). Crude
extracts contain the full array of major allergens that a patient can be
sensitized to, which increases likelihood of therapeutic efficacy in
patients without the need of component-resolved diagnosis prior to
treatment. Additionally, crude extracts also contain numerous non-
protein constituents such as chitins, b-glucans, and endotoxins, all of
which can act on innate immune cells in a pro-inflammatory fashion,
which might interfere with the tolerance-inducing capacity required
for successful therapy.7 In contrast, use of purified proteins allows
for treatment with specific allergens in the absence of such compo-
nents contained within extracts.8 This is expected to enhance SIT
efficacy by more efficiently inducing a tolerogenic response due to
the absence of TLR agonists during allergen administration, harness-
ing an immunoregulatory phenotype of the allergen-presenting cell
upon SCIT.1 Moreover, use of purified allergens in combination with
a component-resolved diagnosis of sensibilization patterns holds the
promise of personalized intervention strategies in immunotherapy.8
However, it is currently unknown whether purified allergens are a
more efficient treatment modality than full allergen extracts.
House dust mite (HDM) is the most prominent source of indoor
exposure to allergens and is a cause for allergic rhinitis and asthma.9
The HDM species Dermatophagoides pteronyssinus (Der p) has at least
23 major allergens9 that are thought to contribute to allergic sensitiza-
tion through their proteolytic activity, activating cells of the innate
immune system and priming an adaptive type 2 immune response.2,9 In
the MAS prospective birth cohort, sensitization patterns for HDM aller-
gens were studied into detail by component-resolved analysis.10
Herein, specific IgE (spIgE) for Der p1, 2, and 23 can be detected before
sensitization to any of the other major allergens. Moreover, sensitiza-
tion to Der p1, 2, and 23 allergens has the highest prevalence, with
more than half of the 20-year-old individuals having spIgE to group 1
and 2 allergens.10 Interestingly, early onset of sensitization to group 1,
2, or 23 allergens was associated with sensitization to more HDM aller-
gens and with allergic rhinitis and asthma at school age, indicating the
clinical relevance of these sensitization patterns.10 Treatment options
for HDM allergy include allergen avoidance and SIT.11 However, HDM
extracts are variable in content of allergens,12,13 and stability is lim-
ited.14 Given the fact that sensitization to Der p1 and 2 identifies more
than 95% of HDM-allergic individuals9,13 and their causal role in early
sensitization,10 SIT with purified Der p1 and 2 might be a more attrac-
tive therapeutic approach compared to the use of HDM extracts.
Here, we test the hypothesis that treatment with natural purified
Der p1 and 2 is an effective treatment in inducing a protective neu-
tralizing antibody response and in suppressing allergic inflammation
in a mouse model of HDM-driven allergic asthma. We find that SCIT
with a mixture of Der p1 and 2 is superior to extract in suppressing
Th2 cell activity and inducing neutralizing antibodies, and equally
capable of suppressing manifestations of allergic airway inflammation
upon challenges in sensitized mice.
2 | METHODS
2.1 | Purification of crude HDM extracts
Freeze-dried Dermatophagoides pteronyssinus extracts were prepared
from whole mite bodies (12C27, Citeq biologics, Groningen, the
Netherlands) and contained 28.5 mg purified Der p1 and 1.8 mg
purified Der p2/g dry weight (ELISA), 439 mg/g protein (BCA), pyre-
tic activity of 5.8 9 106 EU/g (endotoxin assay), and
<3 9 103 KVE/g bioburden (TSA). Purification of groups 1 and 2
from Der p was performed by ion exchange and size exclusion chro-
matography as previously described.15-18 Purified proteins were sep-
arated by SDS-PAGE to evaluate purity and stability (Figure 1).
2.2 | Experimental animals
BALB/cByJ mice were purchased from Charles River Laboratories
(L’Arbresle, France) at an age of 6 to 8 weeks and housed in individu-
ally ventilated cages (IVC). Animal housing and experiments were per-
formed in accordance with the guidelines of and after written
approval by the Institutional Animal Care and Use Committee at the
University of Groningen. All groups consisted of eight female mice.
2.3 | Allergic asthma treatment protocol
All mice received injections of 5 lg crude extract HDM adsorbed to
2.25 mg Alum (Imject, Pierce) in 100 lL PBS (Figure 2A). Subcuta-
neous immunotherapy (SCIT) was performed by three injections on
alternate days,19 using 250 lg crude extract HDM, or naturally puri-
fied Der p1 and 2 in a 50/1 ratio (100 lg DerP1/2), applied either
in 100 lL PBS or as freshly prepared emulsions of the purified
DerP1/2 solution in SAINT lipids (Synvolux, the Netherlands), at a
concentration of 5, 10, or 20 lg DerP1/2 in, respectively, 75, 150,
or 300 nmol SAINT (Figure 6B). Challenges were performed by intra-
nasal installation of 25 lg HDM. Hereafter, airway responsiveness
was determined, and bronchoalveolar lavage fluid (BALF), lungs, and
blood were collected and stored for analyses.
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2.4 | Ear swelling response (ESR)
Before and after SCIT treatment, an ear swelling test (EST) was per-
formed to evaluate the early-phase response to HDM to test for
allergic sensitization, as previously described.7,19
2.5 | Measurement of airway hyperreactivity to
methacholine
Airway hyperresponsiveness (AHR) was assessed by measuring air-
way resistance (R in cmH2O.s/mL) and lung compliance (C in mL/
H2O) in response to intravenous administration of increasing doses
of methacholine (Sigma-Aldrich, MO).19,20 Next, AHR was expressed
as the effective dose of methacholine required to induce a R of 3
cmH2O.s/mL (ED3).
2.6 | Bronchoalveolar lavage fluid (BALF)
Lungs were lavaged, and cytospin preparations were made according
to previous published protocols.19
2.7 | T-cell responses: restimulation of lung cells
Lung single cell suspensions (5 9 105/well) were stimulated for
5 days in RPMI1640 with 0 or 10 lg of DerP1/2 per well, and
supernatant was stored in triplo (80°C). ELISA determined the
F IGURE 1 Evaluation of crude extract house dust mite (HDM) and naturally purified Der p1 and 2. A, Purified proteins were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis SDS-PAGE in four different conditions: 1, zero hour; 2, 46-h incubation at 4°C; 3,
46-h incubation at room temperature; 4, 46-h incubation at 37°C. On the left, the marker (M) is consistent throughout all gels. B, left: Analysis
of purified Der p1 by PAA gel electrophoresis identifying three smaller fragments, sized 25, 17, and 14 kDa. B, right: Protein BLAST against
full-length Der p 1 of peptides identified by Maldi-TOF from purified bands a, b, and c
864 | HESSE ET AL.
F IGURE 2 Overview and immunoglobulin response after subcutaneous immunotherapy (SCIT) treatment. A, Outline of the SCIT protocol.
B, Outline of the treatment groups. C, House dust mite (HDM) specific IgG1, Der p1 specific IgG1, and Der p2 specific IgG1 levels measured
in sera taken after SCIT and after challenges (arbitrary units (AU)/mL, post-SCIT and postchallenges). D, House dust mite (HDM)-spIgG2a, Der
p1-spIgG2a, and Der p2-spIgG2a levels measured in sera taken before and after challenges (AU/mL, post-SCIT and postchallenges). E, House
dust mite (HDM)-spIgE, Der p1-spIgE, and Der p2-spIgE levels measured in sera taken before and after challenges (AU/mL, post-SCIT and
postchallenges). F, Total IgE (ng/mL) levels measured in sera taken before and after challenges (ng/mL, post-SCIT and postchallenges), and the
neutralizing activity plotted as ratio of Der p1-spIgG1/Der p1-spIgE levels in post–SCIT-sera (middle) and post–challenge-sera (right). In
Figure 1C-F, values are expressed as mean  SEM (n = 8). The neutralizing activities in Figure 1F are expressed in the box-and-whisker plots
(min-max). *P < .05, **P < .01, and ***P < .001 compared to PC at the same time point. NC: Negative control, PBS challenged; PC: positive
control, HDM challenged; HDM and DerP1/2: different SCIT-treated mice, HDM challenged
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concentrations of IL-5, IL-10, IL-13 and IFN-c, according to the man-
ufacturer’s instructions (BD Pharmingen, CA).
2.8 | Analysis of cytokine levels in lung tissue
The right superior lobe was used for measurement of total
protein, and concentrations of IL-4, IL-5, IL-10, IL-13, IL-17, IL-33,
IFN-c, eotaxin/CCL11, TARC/CCL17, and MIP3-a/CCL20
were measured using a MILLIPLEX Map Kit (Merck Millipore
Corp., Germany) and analyzed according to the manufacturer’s
protocol.
2.9 | HDM and Der p1 and Der p2 specific
Immunoglobulins
Blood was collected at several time points in the experiment (pre-
and postserum). House dust mite (HDM)-spIgE, Der p1-spIgE and
p2-spIgE, Der p1-spIgG1, and Der p1-spIgG2a levels were measured
by ELISA in a similar protocol as described previously7 and in
Table S1.
2.10 | Statistical analyses
All data are expressed as mean  SEM. The Mann-Whitney U test
was used to analyze the results, and P < .05 was considered signifi-
cant. Within the AHR measurements, a generalized estimated equa-
tion (GEE) analysis was used, using SPSS Statistics 20.0.0.2.21
Nonparametric Spearman’s correlations were performed in Figure 5D,E.
See additional methods descriptions in the online supplemental
methods.
3 | RESULTS
3.1 | Preparation, stability, and purity of natural
Der p1 and Der p2
To establish a purified DerP1/2 vaccine, we optimized biochemical
purification from aqueous extracts of whole mite cultures and ana-
lyzed protein stability (Figure 1A). Both Der p1 and 2 are stable for
prolonged period of time, with minor loss of protein intensity after
46 hours of incubation at 37°C. Analysis of Der p1 revealed the
presence of smaller fragments, sized 25 kDa (a), 17 kDa (b), and
14 kDa (c, Figure 1B). These fragments correspond to Der p1
breakdown products given the endogenous cysteine protease activ-
ity of Der p1.11,12 Maldi-TOF analysis on these fragments confirmed
their identity as Der p1 peptides (Figure 1B). Using these Der p1
and 2 batches, we generated a DerP1/2 vaccine by mixing in a
50:1 w/w ratio.
3.2 | DerP1/2-SCIT enhances HDM-spIgG2a levels
Next, we aimed to test whether purified Der p1 and 2 proteins
showed clinical efficacy in our SIT model. House dust mite (HDM)-
sensitized mice received SCIT with DerP1/2 or HDM, or PBS con-
trol, followed by HDM challenges to evaluate whether the allergic
response is suppressed by SCIT (Figure 2A,B). As SCIT induces a
neutralizing antibody response,1 we evaluated spIgG1, and spIgG2a
after SCIT (post-SCIT) and after challenges (postchallenge, Figure 2C,
D). SCIT with either DerP1/2 or HDM did not affect HDM-spIgG1
levels after treatment, or at the time of challenges. In contrast, only
DerP1/2-SCIT was able to induce a significantly increased HDM-
spIgG2a response, at both time points.
3.3 | DerP1/2 and HDM-SCIT enhance Der p1-
spIgG1 and Der p1-spIgG2a
As we used purified Der p1 and 2, we also analyzed Der p1 and 2
specific immunoglobulins. Here, we observed increased Der p1-
spIgG1 levels after DerP1/2-SCIT (Figure 2C). Subsequent challenges
resulted in increased Der p1-spIgG1 levels in both HDM-SCIT and
DerP1/2-SCIT groups.
For Der p1-spIgG2a, we observed a significant increase after
DerP1/2-SCIT; while in the HDM-SCIT group, increased Der p2-
spIgG2a levels were only detected after allergen challenges (Fig-
ure 2D). Der p2-spIgG1 or Der p2-spIgG2a responses were not
observed in any of the groups.
3.4 | Specific IgE responses after DerP1/2-SCIT and
HDM-SCIT
Remarkably, most of the positive controls failed to induce a suffi-
ciently high IgE response, visualized in the total IgE and HDM-spIgE
levels plotted in Figure 2E,F. Therefore, when both HDM-SCIT and
DerP1/2-SCIT groups were compared to these positive controls, we
found significant increases at both time points. Also, levels of Der
p1-spIgE and 2-spIgE were significantly increased after both HDM
and DerP1/2-SCIT compared to controls (Figure S1A).
Clinical efficacy of SIT is associated with the neutralizing capacity
of the spIgGs,4 while symptom score in allergic asthma is inversely
correlated to the ratio of spIgG over spIgE,22 indicating the relevance
of IgG response induced during SIT. Therefore, we calculated the
changes in the ratio of Der p1-spIgG1 over Der p1-spIgE and com-
pared between groups (Figure 2F). We find significantly increased
spIgG/spIgE ratios both before and after challenges with DerP1/2-
SCIT compared to positive controls. House dust mite (HDM)-SCIT
mice, however, only display an increased IgG/IgE ratio after HDM
challenges, but not after SCIT. A complete overview of all ratios is
plotted in Figure S1B. These analyses reveal that Der p1-spIgG1 is
the main isotype of neutralizing antibodies induced by SCIT in our
experiment.
3.5 | HDM-SCIT reduces the early-phase response
to HDM
Next, we aimed to evaluate whether SCIT protected against the
early IgE-mediated responses upon challenges. To this end, we
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performed an ear swelling test (EST) by HDM injection before and
after SCIT. In HDM-sensitized mice, intradermal HDM injection
resulted in a positive ear swelling, confirming allergic sensitization
(Figure S2A). The EST after SCIT resulted in a significantly decreased
swelling in HDM-SCIT mice as compared to controls (Figures 3A,
S2B). The suppression of swelling in DerP1/2-SCIT mice, however,
was less substantial and showed a trend toward significance.
3.6 | DerP1/2-SCIT and HDM-SCIT suppress
airway hyperresponsiveness
To evaluate whether treatment protected against phenotypes of
asthma, we assessed the effect of SCIT on lung function after HDM
challenges. We measured AHR to methacholine and calculated the dose
of methacholine required to induce a resistance of 3 cmH2O.s/mL (ED3;
F IGURE 3 Clinical manifestations after subcutaneous immunotherapy (SCIT) treatment. A, IgE-dependent allergic response plotted as net
ear thickness (lm) 2 h after house dust mite (HDM) injection (0.5 lg) in the right ear and PBS in the left ear as a control, performed after
SCIT. Placebo-SCIT–treated mice were plotted together as controls (NC and PC). B, Effective dose (ED) of methacholine, when the airway
resistance reaches 3 cmH2O.s/mL (ED3). C, Airway hyperreactivity (AH) was measured by FlexiVent and plotted as airway resistance (R in
cmH2O.s/mL) and as (D) airway compliance (C in mL/cmH2O). Absolute values are expressed as mean  SEM (n = 8). *P < .05, **P < .01, and
***P < .001 compared to PC. NC: Negative control, PBS challenged; PC: positive control, HDM challenged; HDM and DerP1/2: different SCIT
treatments, HDM challenged
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Figure 3B). Herein, both HDM-SCIT and DerP1/2-SCIT show a trend
toward increased ED3 compared to the positive controls. Next, we com-
pared the resistance across all dose-response curves and found that
both HDM-SCIT and DerP1/2-SCIT were significantly reduced, as evi-
denced from a right shift of curves and a reduced plateau at higher con-
centrations (Figure 3C). In addition, while we observed significantly
F IGURE 4 The eosinophilic and cytokine response after subcutaneous immunotherapy (SCIT) treatment. A, Differential cytospin cell
counts in bronchoalveolar lavage fluid (BALF). M: Mononuclear cells, E: eosinophils, N: neutrophils. Absolute numbers are plotted in the
box-and-whisker plots (min-max). B, Bronchoalveolar lavage fluid (BALF) eosinophils, plotted as fold suppression (absolute eosinophils/
average PC-eosinophils; mean  SEM). C, Bronchoalveolar lavage fluid (BALF) IL-5 levels (pg/mL) (mean  SEM). D, Net levels of IL-5, IL-
10, and IL-13 measured in restimulated lung single cell suspensions. Concentrations were calculated as the concentration after
restimulation minus control and plotted in the box-and-whisker plots (min-max). *P < .05, **P < .01, and ***P < .001 compared to PC.
NC: Negative control, PBS challenged; PC: positive control, HDM challenged; HDM and DerP1/2: different SCIT treatments, HDM
challenged
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reduced compliance in HDM-challenged mice, both HDM-SCIT and
DerP1/2-SCIT did not improve lung compliance (Figure 3D).
3.7 | HDM and DerP1/2-SCIT suppress eosinophilic
airway inflammation and cytokine levels
Successful SIT is associated with suppression of Th2 cell activity and
reduced airway inflammation upon challenges. Therefore, we
assessed inflammation and Th2 cytokines in bronchoalveolar lavage
fluid (BALF). As expected, HDM challenges in positive controls
induced a pronounced eosinophilic airway inflammation (Figures S2C
and 4A,B). Both HDM-SCIT and DerP1/2-SCIT resulted in markedly
decreased eosinophil numbers in BAL, with a relative eosinophil sup-
pression by both treatments of ~5-fold compared to controls (Fig-
ure 4B). To evaluate the activity of the Th2 cells and ILC2s, we
analyzed levels of IL-5, IL-10, and amphiregulin in BALF and
observed a significantly reduced IL-5 level only in DerP1/2-SCIT–
treated mice, when compared to positive controls (Figure 4C), while
IL-10 and amphiregulin levels were unaffected by either treatment
(Figure S2D,E).
Next, we analyzed allergen-specific Th cell activity by measuring
cytokine release in the supernatant of restimulated lung cell suspen-
sions. Here, we observed a significantly reduced production of IL-5
(only in HDM-SCIT) and IL-13 levels in HDM-SCIT and DerP1/2-
SCIT mice compared to controls (Figure 4D). Interestingly, in both
SCIT groups, we also observed an increased IL-10, indicating the
presence of regulatory T cells.
3.8 | HDM and DerP1/2-SCIT suppress type 2
responses
Given the somewhat contrasting results of the type 2 cytokines in
BALF and in restimulated cell suspensions, we also analyzed the
levels of the signature type 2 inflammatory cytokines in lung tis-
sue of HDM-treated, DerP1/2-treated, and sham-SCIT–treated
mice. Here, we find that HDM challenges in sham-treated mice
induced a strong IL-4, IL-15, and IL-13 response compared to neg-
ative controls (Figure 5A). SCIT with DerP1/2, but not with HDM,
was able to suppress IL-4 and IL-5, while IL-13 was not affected
by either treatment. In contrast, we find that HDM-SCIT and
DerP1/2-SCIT did not induce increased levels of IL-10 in lung
tissue (Figure 5B). We also measured IFN-c levels to control for
any effect on Th1 cell activity and found no induction in this
model.
3.9 | DerP1/2-SCIT suppresses release of the
epithelial chemokine CCL20
To test whether SCIT also affected the innate response to allergens,
we assessed levels of pro-inflammatory chemokines and alarmins
released by lung structural cells upon HDM exposure.7 Here, we
observe that challenges clearly induced release of eotaxin, IL-33,
TARC/CCL17, and MIP3a/CCL20 indicating activation of the innate
immune system and structural cells (Figure 5B,C). Interestingly, we
observed that only DerP1/2-SCIT resulted in suppression of CCL20
levels and showed a trend toward suppression of eotaxin, IL-33, and
CCL17 levels in lung tissue. No significant effect of SCIT on IL-17
was observed (data not shown).
Next, we asked whether the levels of the Der P1 specific neu-
tralizing antibodies after SCIT correlated with a decreased AHR or
immunological response after HDM challenges. Here, we found a
negative correlation between Der p1-spIgG1 (post-SCIT) vs the lung
cytokines IL-4, IL-5, and CCL20 and BALF IL-5 levels (Figure 5D,E).
In contrast, we did not observe a significant correlation between the
Der p1-spIgG1 levels and the more translational parameters ED3 or
the EST.
3.10 | DerP1/2-SCIT dose dependently modifies
the allergic immune response
Finally, we asked whether the use of purified DerP1/2 would allow
use of a lower dosage of protein for successful treatment. To this
end, we used three dosages of 5, 10, and 20 lg of DerP1/2 vaccine
complexed to SAINT for improved delivery, and compared the effect
of DerP1/2-SCIT to SAINT-only control treatment (Figure 6A,B).23
We find that low DerP1/2 dosages do not suppress ESR after chal-
lenge. In contrast, the highest dose of the DerP1/2-SCIT groups did
induce significant suppression compared to SAINT-treated controls
(Figure 6C). In addition, the DerP1/2 vaccine dose dependently mod-
ified eosinophilic inflammation and AHR (Figure 6D,E). Remarkably,
low-dose DerP1/2 exaggerated eosinophilic inflammation and AHR.
In contrast, 20 lg DerP1/2 did show therapeutic effect, albeit lim-
ited, in suppressing AHR, while airway eosinophilia was not sup-
pressed. All three doses of DerP1/2 failed to suppress IL-4, IL-5, and
IL-17 levels in lung tissue. Furthermore, only the highest dose of
DerP1/2 was able to suppress IL-33 (Figure 6F).
Overall, while the lowest dose of the DerP1/2 vaccine exagger-
ated the allergic phenotype, the use of 20 lg was capable of sup-
pressing some of the allergic asthma parameters, such as AHR and
lung tissue IL-33. Taken together, these data indicate that DerP1/2
is able to modify the allergic immune response, with higher levels
inducing a suppression of allergic inflammation and achieving an
enhanced lung function.
4 | DISCUSSION
In this study, we asked whether purified Der p1 and 2 would have
superior activity in DerP1/2-SCIT compared to HDM extracts. A
direct comparison of both treatments clearly indicates that the
DerP1/2 vaccine results in marked suppression of type 2 cytokine
levels in lung and BALF, and increased Der p1-spIgG responses. The
levels of Der p1 specific IgG1 after SCIT were negatively correlated
to levels of IL-5, IL-13, and CCL20 after HDM challenge, indicating a
protective role for this neutralizing antibody response in our mouse
model. Moreover, DerP1/2-SCIT was uniquely able to prevent the
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HDM challenge-induced increase in CCL20/MIP3-a levels, and a
similar trend was observed toward preventing the HDM-induced
CCL17/TARC and eotaxin response in lung tissue. While these
immunological parameters argue in favor of DerP1/2-SCIT, we do
not observe differences in the more translational parameters of
AHR, EST, and eosinophilia, where both treatments have similar effi-
cacy in suppressing the allergic responses. Hence, we postulate that
DerP1/2-SCIT is at least as effective in suppressing the HDM-
induced adaptive and innate responses as whole body extracts, war-
ranting translational studies to evaluate whether a similar approach
is also efficacious in men.
The difference in suppression of type 2 cytokines and induction
of neutralizing antibody responses might be the result of the higher
protein dose of Der p1 and 2 that is achieved by administration of
purified allergens compared to full extract, which contained 28.5 mg
Der p1 and 1.8 mg Der p2 per gram dry weight. Of note, we only
observe a spIgG response to Der p1 after DerP1/2-SCIT. The
absence of a Der p2-spIgG response after the Der P1/2-SCIT could
be explained by the use of Der p1 and 2 in a 50:1 molar ratio. Con-
sequently, most of the effects in this model might depend on modu-
lation of the Der p1 specific response. Altering the ratio of Der p1
to Der p2 to also induce a Der p2-spIgG response might further
improve the efficacy of the vaccine. Moreover, addition of Der p23
into the mixture might further increase the value of a vaccine, as, in
adults, sensitization to Der p1, 2, and 23 allergens has the highest
prevalence, and sensitization to these allergens precedes that of
other major Der p allergens, indicating their critical role in HDM
allergy.10
Another potential advantage of the use of purified proteins over
an extract for SIT is the lack of nonprotein constituents of the
extracts, including chitin, beta-glucans, and endotoxins. These con-
taminants might activate a pro-inflammatory innate response upon
injection of the vaccine. We observe a reduction in HDM-induced
CCL20 levels and a trend toward reduction in CCL11/eotaxin,
CCL17/TARC, and IL-33 levels in DerP1/2-SCIT mice, which might
reflect a reduced activation status of the innate immune system. In
agreement herewith, it has been reported that full extract challenges
in allergic asthma patients induced a stronger late allergic response
compared to challenges with Der p1 and 2, while early responses
were identical, which was attributed to nonprotein constituents of
the HDM extract.24
Pro-inflammatory activation of the antigen-presenting cell during
SCIT might also negatively influence the induction of a tolerogenic
T-cell response.25 However, some studies have reported successful
use of TLR agonists as adjuvants for allergen immunotherapy,
including monophosphoryl lipid A26 or bacterial DNA rich in CpG
motifs,27 indicating that activation of specific PRRs may in fact be
beneficial in SIT. Notwithstanding, using biochemically and pharma-
cologically defined products for SIT will increase quality of the
treatment.
Other approaches to develop novel therapeutic allergy vaccines
for use in SIT for HDM include the generation of recombinant
hypoallergenic combination vaccines of Der p1 and 2, which were
shown to have limited IgE reactivity, while retaining its T-cell epi-
topes and the ability to induce neutralizing antibody response in
experimental models that could block IgE binding.11,28 The use of
these hypoallergenic recombinant vaccines holds the promise of
inducing fewer side effects during therapy. Der p1 peptides have
also been delivered on virus-like particles, inducing IgG responses
within 4 weeks after a single injection in healthy subjects.29 Both of
these approaches involve the use of recombinant hypoallergenic pro-
teins or peptides, while we use purified natural proteins, with high
purity and pharmacologically well defined, but retaining the activity
to crosslink IgE. Although hypoallergenic proteins are considered to
have a better safety profile during treatment, is currently unknown
whether hypoallergenic vaccines have a comparable therapeutic effi-
cacy compared to IgE-activating allergens. Initial studies show that
hypoallergenic proteins can induce neutralizing antibodies that inhibit
allergen-mediated cross-linking of IgE.11,30 IgE cross-linking vaccines
might have some additional therapeutic efficacy due to so-called
piecemeal degranulation of mast cells and basophils, which is
thought to contribute to protection against allergic responses espe-
cially during the early phase of treatment due to inactivation or
exhaustion of these effector cells.30 Further research will need to
establish whether purified natural allergens, that can be produced in
relatively high quantities under strictly controlled conditions at rela-
tively low costs and address both effector cell responses, B-cell and
T-cell activity, or recombinant hypoallergenic or peptide vaccines
that require far higher production costs and mainly address the T-
cell response, will be the most optimal treatment for SIT.
We provide evidence that Der p1 and 2 can be used as a phar-
macologically well-defined SIT in the HDM-sensitized host to sup-
press allergic responses, with superior activity compared to HDM
extract with regard to Th2 cell cytokines as well as the chemokines
and alarmins released by the lung structural cells upon HDM expo-
sure. House dust mite (HDM) extract and purified allergens were
equally effective in suppressing eosinophilic airway inflammation and
AHR. These data warrant clinical studies to explore the safety and
F IGURE 5 Overview of cytokine profile after subcutaneous immunotherapy (SCIT) treatments, measured in lung tissue dissolved in
Luminex buffer. A, Type 2 inflammatory cytokines IL-4, IL-5, and IL-13 (pg/mg) in lung tissue of house dust mite (HDM)-treated, DerP1/2-
treated, and sham-SCIT–treated mice. B, IFN-c, IL-10, and eotaxin/CCL11 levels (pg/mg) quantified via Luminex in lung tissue. C, Indicators of
the activation of the innate immune system, IL-33, TARC/CCL17, and MIP3a/CCL20 in lung tissue after HDM challenges. D, Nonparametric
Spearman’s correlations of post-SCIT Der p1-spIgG1 vs lung cytokines IL-4 (r = .535) and IL-5 (r = .434). E, Nonparametric Spearman’s
correlations of post-SCIT Der p1-spIgG1 vs lung CCL20 (r = .583) and BALF IL-5 (r = .685). Concentrations (pg/mg) are expressed as
mean  SEM (n = 8). *P < .05, **P < .01, and ***P < .001 compared to PC. NC: Negative control, PBS challenged; PC: positive control, HDM
challenged; HDM and DerP1/2: different SCIT treatments, HDM challenged
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efficacy of the use of these purified natural allergens as a novel vac-
cine for HDM-induced allergic disease, including rhinitis and allergic
asthma.
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